secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2022-03-04T23:59:59+00:00
Accession:  0001104659-22-030652
Event type: other
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech grants 136,000 stock options to CEO, CFO, and President at $3.71
------------------------------------------------------------------------------

- Pardeep Nijhawan (CEO) granted 49,000 options; monthly vesting over 36 months, 10-year term.
- Kathi Niffenegger (CFO) granted 43,500 options; Michael Brooks (President) also granted 43,500 options.
- Exercise price set at $3.71 per share, equal to closing price on grant date (Feb 28, 2022).
- Options vest monthly over 36 months; no immediate change in executive compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000110465922030652/0001104659-22-030652-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000110465922030652/tm228418d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-030652

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer